Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term antiretroviral therapy outcomes in acute HIV infection
ChiCTR1800015006Phase 4Recruiting
- Sponsor
- NHC Key Laboratory of AIDS Immunology (China Medical University), The First Affiliated Hospital
- Start
- Jan 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir disoproxil fumarate, lamivudine, efavirenz, lopinavir and ritonavir in human immunodeficiency virus infection (HIV), sponsored by NHC Key Laboratory of AIDS Immunology (China Medical University), The First Affiliated Hospital. Primary endpoints: HIV viral load and CD4 T-cell count. Started Jan 2018; status: recruiting.
02
Drugs
tenofovir disoproxil fumaratelamivudineefavirenzlopinavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR1800015006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015006.